Kanghong Pharmaceutical and Vanotech Ltd. today announced the successful completion of a Phase 2b clinical trial evaluating KH607 in adults with major depressive disorder (MDD). HIGHLIGHTS Phase 2b ...

A new meta-analysis shows meaningful differences among FDA-approved antipsychotic adjuncts for MDD, with lumateperone showing the strongest efficacy and aripiprazole the best overall acceptability.

Major Depressive Disorder (MDD) is far from a cookie-cutter diagnosis. Different patients report suffering from different subsets of symptoms, yet most are ultimately prescribed the same first-line ...

Among people with major depressive disorder, treatment with semaglutide reduces the perceived cost of effort and improves motivation.

A new study uses real-time fMRI neurofeedback to help depression patients reduce rumination by training specific brain ...

Neurons and white blood cells differ greatly in shape, function, and location within the body. However, researchers at the ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

Before your first psychiatrist appointment for major depressive disorder, you can do many things to prepare. By planning ahead, you’re doing everything on your end to make sure you have a smooth ...

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a ...